David Isaacs, MD

David
Isaacs
MD
Associate Professor
Neurology

David Isaacs is an Assistant Professor of Neurology at Vanderbilt University Medical Center with fellowship-training in movement disorders. Clinically, he is part of the VUMC Parkinson’s Disease Center of Excellence, Huntington’s Disease Center of Excellence, and Deep Brain Stimulation Clinic. In 2019, he founded the Vanderbilt Adult Tourette Syndrome Clinic to promote specialized clinical care and advance research initiatives in this patient population. In collaboration with Dr. Heather Riordan, he established the Vanderbilt Tourette Syndrome Working Group in 2020, a cross-disciplinary, trans-institutional consortium that meets monthly to review journal articles, discuss challenging clinical case, and develop research projects centered on Tourette syndrome. In 2021, he received the Vanderbilt Faculty Research Scholar Award, a career development award that will provide protected time and pilot funding to support his Tourette syndrome research.

Dr. Isaacs is a current member of the Movement Disorders Society and the Vanderbilt Kennedy Center. In 2015, he received both the Medical Student Teaching Award and the James Tru Martin Award for the Vanderbilt Department of Neurology. 

Dr. Isaacs earned his B.S. in Biophysics from the University of Southern Indiana and subsequently graduated from medical school at the Indiana University School of Medicine. He completed his neurology residency at Vanderbilt University Medical Center in 2015, serving as Chief Resident his final year. The following year he completed his Movement Disorders Fellowship at Vanderbilt before joining the faculty in 2016. In 2019, he earned his master’s degree in public health. 

Dr. Isaacs’ research interests primarily focus on the following: 1) Tourette syndrome, 2) non-motor manifestations of movement disorders; 3) translational neurophysiologic biomarkers; and 4) neuromodulation.

He oversees longitudinal studies assessing non-motor manifestations of Huntington’s disease, Parkinson’s disease, and Tourette syndrome; each of these projects are actively enrolling subjects. He is employing event-related potentials and quantitative electroencephalography to detect novel brain-based indicators of sensory dysfunction in Tourette syndrome, with the ultimate intent to identify and validate translational neurophysiologic biomarkers. 

Dr. Isaacs serves as site principal investigator for several industry-sponsored clinical trials in Tourette syndrome. Additionally, he participates as co-investigator and/or rater in clinical trials for Parkinson’s disease, Huntington’s disease, dystonia, and spasticity.

Jane E. Howard, MD

Jane
E.
Howard
MD
Assistant Professor
Neurology

Dr. Howard is Assistant Professor of Neurology at Vanderbilt University Medical Center. She joined the faculty in 1991, and specializes in neuromuscular disorders. Dr. Howard is board certified in Psychiatry and Neurology, as well as Electrodiagnostic Medicine.

Dr. Howard graduated with departmental honors and cum laude recognition from Washington University in 1978, receiving an AB in Mathematics. She earned her medical degree from the University of Florida in 1982, and served her internship in Internal Medicine at Stanford University Hospital. In 1986 Howard completed a neurology residency at Stanford University Hospital and received her neuromuscular fellowship training at Palo Alto VA Hospital and Stanford University Hospital. From 1988 –1991 Howard was a Dana Foundation Fellow in Neuroscience at Stanford University. 

Timothy J. Hohman, PhD

Timothy
James
Hohman
PhD
Professor
Neurology

Dr. Timothy Hohman is a Professor of Neurology, cognitive neuroscientist, and computational geneticist. Dr. Hohman’s research leverages advanced computational approaches from genomics, proteomics, and neuroscience to identify novel markers of Alzheimer’s disease risk and resilience. He leads the Biomarker Core for the Vanderbilt Memory & Alzheimer’s Center and holds leadership positions in multiple international consortia, including serving as the Contact-PI for the Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC; U24-AG074855) and directing the Genomics Core for the Preclinical Alzheimer’s Consortium.

Dr. Hohman received his BA in Psychology (magna cum laude) from Gordon College, followed by his MA in Psychology from American University. He received his doctoral degree in neuroscience from American University focusing on cognitive and neural changes during normal aging. He also completed a fellowship as part of the National Institutes of Health Graduate Partnership Program in the Laboratory of Behavioral Neuroscience at the National Institute on Aging.  He completed his postdoctoral training at Vanderbilt where he was a T32 postdoctoral research fellow as part of the Neurogenomics training program in 2012, a recipient of the Pharmaceutical Research and Manufacturers of America Foundation postdoctoral fellowship in translational medicine and therapeutics in 2013, and a K12 Building Interdisciplinary Research Careers in Women’s Health Scholar in 2015.Building Interdisciplinary Research Careers in Women’s Health Scholar in 2015. 

Dr. Hohman’s programmatic research focuses on understanding how certain individuals are able to accumulate Alzheimer’s disease neuropathology without showing clinical symptoms of the disease. He has identified molecular drivers of such resilience through genomic and proteomic analyses leveraging neuroimaging and neuropathology endophenotypes. Dr. Hohman’s team also integrates these diverse data types into a precision medicine approach, focusing on characterizing the best predictors of risk and resilience given an individual’s age, sex, genetic, and neuropathological context. Through transdisciplinary collaboration, Dr. Hohman’s team seeks to facilitate a more rapid move from genomic discovery to therapeutic development.

More information on Dr. Hohman’s research can be found on the VMAC website.

Computational Neurogenomics Team

Amanda C. Hicklin, MSN

Amanda
C.
Hicklin
MSN
Assistant
Neurology

Amanda Hicklin is an Advanced Practice Nurse specializing in Neurology at Vanderbilt University Medical Center. As an outpatient nurse practitioner, she diagnoses and treats patients with a variety of sleep disorders and complex neuromuscular disorders. She is a member of the American Academy of Nurse Practitioners.

Prior to her current role at Vanderbilt, Amanda worked as a nurse practitioner in a variety of clinical settings. She also gained experience as an ECMO specialist at VUMC.

Amanda received an associate degree in respiratory sciences from Itawamba Community College. After working as a registered respiratory therapist for several years, she later earned her Master of Science in Nursing from Vanderbilt University. 

Travis Hassell, MD, PhD

Travis
Hassell
MD, PhD
Assistant Professor
Neurology

Dr. Travis Hassell is an Assistant Professor of Neurology specializing in Movement Disorders at Vanderbilt University Medical Center. His clinical practice and research focuses both on movement disorders and bioengineering, with an emphasis on developing new device technologies such as adaptive deep brain stimulation (DBS). Dr. Hassell also provides instruction in inpatient and outpatient clinical settings for medical students and residents. He is currently a member of the North American Neuromodulation Society, the Movement Disorders Society, the American Academy of Neurology, and the Biomedical Engineering Society (BMES). 

Prior to his current appointment, Dr. Hassell completed a Movement Disorders Fellowship at VUMC. He earned his MD from the Indiana University School of Medicine in 2012, and subsequently completed his medical internship at St. Elizabeth Medical Center (Youngstown, OH) and Neurology residency at Indiana University (Indianapolis, IN), serving as Chief Resident his final year. Dr. Hassell earned his doctorate in Biomedical Engineering from Purdue University (West Lafayette, IN), graduating summa cum laude with a thesis studying devices for real-time monitoring of central nervous system recovery. He received his BS in Biological Engineering (summa cum laude) from the University of Missouri – Columbia. 

Dr. Hassell’s research interests focus on the intersection of engineering and the treatment of neurological movement disorders. He is currently participating as Primary Investigator (PI) or Sub-PI in clinical trials studying DBS devices.

Ye Han, PhD

Ye
Han
PhD
Research Associate Professor
Neurology

Dr. Ye Han is a Research Associate Professor of Neurology at Vanderbilt University Medical Center, specializing in molecular/cellular mechanism studies of neurological disorders. Her research focuses on studying the structure and function of HCN channels and its auxiliary subunit, TRIP8b in the dorsal hippocampus and related neural circuitry with the hope of finding new therapies to treat neurological diseases. Dr. Han completed her PhD in molecular biology in the laboratory of Drs. Kang Chong and Zhihong Xu at the Chinese Academy of Sciences.

Dr. Han’s research has resulted in important contributions to the understanding of the role of TRIP8b in regulating HCN channel function. In particular, she was the first to report that TRIP8b and HCN interact at two distinct sites and that cAMP may directly compete for binding the HCN CNBD domain to control HCN channel trafficking and function. Subsequently, she identified the first known small molecule inhibitor of the interaction between TRIP8b and HCN using high throughput screening techniques. She recently demonstrated that modulating the TRIP8b-HCN interaction bidirectionally influences channel trafficking and antidepressant-like behavior.

Dr. Han’s current research focuses on developing novel antidepressant therapies based on the lab’s discovery that TRIP8b, an auxiliary subunit of HCN channels, regulates antidepressant-like behavior. She previously demonstrated that TRIP8b regulates HCN channel surface expression and subcellular localization by binding to pore forming subunits at two distinct locations. She subsequently examined the structure-function relationship of TRIP8b mediated HCN channel trafficking using viral mediated rescue experiments in TRIP8b knockout animals. She found that restoring TRIP8b expression to the hippocampi of TRIP8b knockout animals impaired the animal’s performance on screening tests for antidepressant efficacy. She also showed that reducing TRIP8b mediated HCN channel trafficking in the hippocampus improved the animal’s performance on the same tests. These results indicated that inhibiting TRIP8b mediated HCN channel trafficking is a promising target for novel antidepressant therapies.

Mallory Hacker, PhD, MSCI

Mallory
Hacker
PhD, MSCI
Assistant Professor
Neurology

Dr. Hacker is Assistant Professor of Neurology at Vanderbilt University Medical Center. She received the 2019 Kumar New Investigator Award from the North American Neuromodulation Society. She has received funding from the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), the Department of Defense's Congressionally Directed Medical Research Program (CDMRP), the Michael J. Fox Foundation for Parkinson’s Research (MJFF), and the American Parkinson Disease Association (APDA). 

Dr. Hacker earned a B.S. in Chemistry in 2007 from the University of Tennessee at Chattanooga. She attended Vanderbilt University where she earned a Ph.D. in Cell and Developmental Biology studying neurodegenerative pathways arising from Coenzyme Q deficiency in 2013. She received postdoctoral training in neurology clinical research at Vanderbilt University Medical Center (VUMC) and was a visiting assistant professor at the Bloomberg School of Public Health at Johns Hopkins University in 2016. She completed the Vanderbilt School of Medicine Master of Science in Clinical Investigation (MSCI) program in 2019.

Dr. Hacker’s research focuses on understanding the effects of deep brain stimulation (DBS) in very early-stage Parkinson’s disease patients and studying objective methods to evaluate Parkinson’s disease progression. She also investigates the prevalence and impact of spasticity in the long-term care setting as well as ways to improve its screening, referral, and treatment. 

Newswise: Sweet-Spot Brain Stimulation May Halt Parkinson’s Progression

VUMC Reporter: Deep brain sweet spot might be key to halt Parkinson’s

Neurology Advisor: Benefits of Deep Brain Stimulation for Early Stage Parkinson Disease

Technology Networks: 5-year Study Shows the Long-term Efficacy of Deep Brain Stimulation in Parkinson's

Medical Xpress: Nursing home study reveals 'woeful' underdiagnosis of spasticity

VUMC Discover: Reducing Untreated Spasticity in the Elderly

VUMC Reporter: Neuromodulation Society honors Hacker’s Parkinson’s research

The Tennessean: For Parkinson’s patients, a surreal brain surgery offers new hope

VUMC Reporter: DBS treatment may slow tremor progression in early-stage Parkinson’s patients

VUMC Reporter: Trial to test whether DBS slows Parkinson’s progression

 

 

Kevin Haas, MD, PhD

Kevin
Haas
MD, PhD
Division Chief
Epilepsy
Clinical Director
Epilepsy Surgery
Professor
Neurology

Dr. Kevin Haas joined the Vanderbilt Neurology Department faculty in 2004. His clinical focus is epilepsy and he serves as Clinical Director of the Epilepsy Surgery Program and as EEG Laboratory Director.  He rotates as an attending physician on the Neuro-ICU EEG and Epilepsy Monitoring Unit services. He is board certified in Neurology, Epilepsy, and Epilepsy Monitoring.  Dr. Haas is a fellow of the American Epilepsy Society, a fellow of the American Neurological Association, and a member of the American Academy of Neurology.

Dr. Haas earned his BS in biomedical engineering from Duke University in 1991, graduating magna cum laude with distinction. His completed his graduate and medical school training at the University of Michigan, where he earned his PhD degree in neuroscience in 1998 and MD degree in 1999. At Emory University, he completed his internal medicine internship in 2000, neurology residency in 2003, and clinical neurophysiology fellowship with an emphasis in epilepsy in 2004. He served as chief resident in neurology for the 2002-2003 medical year.

Dr. Haas’s clinical research projects focus on epilepsy surgery, ICU-EEG monitoring, epilepsy genetics, and status epilepticus. He is the Vanderbilt site principal investigator for the Critical Care EEG Consortium. In addition, he currently serves as the site principal investigator for multiple clinical trials evaluating new antiepileptic drugs and devices for diagnosis and treatment of medication-resistant epilepsy.  

Dr. Haas’s past research has focused on GABA-A receptor physiology, synaptic roles of ubiquitination, and epilepsy in Angelman syndrome. He is an author on numerous original articles in these fields.

Sarah Graves, MSN, FNP-BC

Sarah
Graves
M.S.
Assistant
Neurology

Sarah Graves is a family nurse practitioner in the Department of Neurology at Vanderbilt University Medical Center, a position she has held since 2016. In her role, she collaborates with a multidisciplinary team to manage the outpatient General Neurology patient population. She assesses, diagnoses and manages patients with a variety of neurological conditions including Alzheimer’s disease, Parkinson’s disease, headache, migraine, essential tremor, multiple sclerosis, and stroke. 

Prior to her current position in the outpatient clinic, Sarah also served as a critical care nurse in the Neurology ICU at VUMC. She received her BSN at Florida Gulf Coast University, and later earned her MSN from Belmont University in 2015. 

Research Presentations

Presented at the 11th Annual Cleveland Clinic Nursing Research Conference in Aurora, OH. Balance, C., Graves, S., Harvey, M., Lucas, E., & Smith, A. (2014). Strategies for medication adherence in patients with type 2 diabetes mellitus: a system review.